UNITY Biotechnology Inc (UBX)

[TradeNaked]

$UBX grabbed some .39sss

[TradeNaked]

Overall market / charts look weak AF still imo . Fed rate news today will flush alot of stocks I think . We’ll see

[surfkast]

Well I am holding for now and watching. Caught the last run.

[TradeNaked]

Honestly seeing this sell of to .30 -.35 :/

[surfkast]

Hope the employees give it a rest dumping their shares.

[TradeNaked]

$UBX looks like one more flush down coming, waiting :)

[surfkast]

But they are paying their employees with stock!
PPS is crashing as they sell!

[conix]

Nice trend. Nice news

https://www.fiercebiotech.com/biotech/unity-shows-promising-results-phase-1-for-advanced-vascular-eye-disease-treatment

[surfkast]

Moving up nicely!

[surfkast]

I am back in! Chart looks great!

[surfkast]

Caution is advised. Too many odd lot trades as low as one share!

A bearish indicator.

[surfkast]

Bid sitting soon?

[surfkast]

Some pre market buying? Maybe I'll jump back in?

[surfkast]

New bottom in?

[TradeNaked]

$UBX .45 buy and hold forever =)

[surfkast]

Still dropping!

[surfkast]

Reversal?

On August 17, 2022, Unity Biotechnology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with SVB Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell 64,285,714 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), and accompanying warrants to purchase up to 64,285,714 shares of Common Stock (the “Warrants”) at a combined public offering price of $0.70 per Share and accompanying Warrant to the Underwriters (the “Offering”).

[Elgordo84]

GLTA

[Elgordo84]

Another beautiful play
$UBX did a 3x in 2 months
Hope ya caught that ride...
You had been warned
$UBX
#ELGORDODAMUS

[surfkast]

That's what happens when employees get paid in shares.
I dumped my freebies today and will look for a bottom.

[willlbone]

Dilution dump

[trendzone]

$12.00,$8.00,$4.00 PT put out this morning, I love the smell of burning flipbags getting manipulated by corrupt MM'S and hedge funds stealing their shares, as I'm also doing right now.

[surfkast]

H.C. Wainwright Remains a Buy on Unity Biotechnology (UBX)

[surfkast]

I will be taking profits today and hold freebies.
The employees here have gotten free stock in lieu of high pay.
I anticipate them cashing out at these levels.

[PStockPickz]

Mayne they let it run again $1.43

[surfkast]

I hope so. Got back in only 11 days ago! WOW!

[PStockPickz]

New High coming ?

[PStockPickz]

Looking great !

[surfkast]

Looking for an entry point before some good news hits?

[surfkast]

FIRM	ANALYST 
 Cantor Fitzgerald 
 Brandon Folkes 
 Citi 
 Yigal Nochomovitz 
 H.C. Wainwright 
 Andrew Fein 
 Mizuho Securities 
 Salim Syed 
 Roth Capital 
 Elemer Piros 
 Wedbush 
 Andreas Argyrides 
 The analysts above have initiated and are maintaining formal research coverage of Unity Biotechnology. Please note that any opinions, estimates or forecasts regarding Unity Biotechnology’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Unity Biotechnology or Unity Biotechnology’s management. Unity Biotechnology does not by reference above or distribution of same imply endorsement of or concurrence with any analyst’s opinions, estimates, forecasts, conclusions or recommendations. Unity Biotechnology does not participate in the preparation of analysts’ reports and undertakes no obligation to verify or correct any information in such reports.

https://ir.unitybiotechnology.com/financial-information/analyst-coverage

[Elgordo84]

Saw this coming !!



Unity Biotechnology (UBX) Receives a Buy from Mizuho Securities

Source: TipRanks
In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Unity Biotechnology (UBX – Research Report), with a price target of $7.00. The company's shares closed last Thursday at $0.77, close to its 52-week low of $0.70. According to TipRanks.com, Syed 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -17.5% and a 34.9% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences. Currently, the analyst consensus on Unity Biotechnology is a Strong Buy with an average price target of $7.00.

[surfkast]

Low enough to take a shot I believe.

[Elgordo84]

Got my attention $UBX

[surfkast]

Turning into pure horse shit.

[4Godnwv]

I’m late to the party, but hopefully she’s working on another leg up

[surfkast]

Employees cashing in their stock awards are killing this one.

https://www.otcmarkets.com/stock/UBX/disclosure

[surfkast]

I believe so. Will take a good look Monday.

[TommyBoyTrader9460]

$UBX Coming off bottom here with volume..adding to watchlist..

https://stockcharts.com/c-sc/sc?s=UBX&p=D&b=5&g=0&i=0&r=1647089563420

[surfkast]

Still watching.

[surfkast]

Looking for a bottom.

[surfkast]

Glad I bailed!

[surfkast]

Took a tax loss. Will buy back in at an appropriate level.

[surfkast]

Mizuho Securities Thinks Unity Biotechnology’s Stock is Going to Recover

[surfkast]

Tax loss selling????

[JOHNNY-VEGAS]

LMAO..look at the chart.

The Company had net losses of $16.5 million and $50.0 million for the three and nine months ended September 30, 2021, respectively, net losses of $27.6 million and $74.3 million for the three and nine months ended September 30, 2020, respectively, and net cash used in operating activities of $40.0 million and $61.6 million for the nine months ended September 30, 2021 and 2020, respectively. To date, none of the Company’s drug candidates have been approved for sale, and therefore, the Company has not generated any revenue from contracts with customers and does not expect positive cash flows from operations in the foreseeable future.

luck is not going to save it and time draining the cash fast.

[surfkast]

What investors are down? This was as low as $2.20 recently. Investors who read the filings should realize that this company needs time and luck.

[JOHNNY-VEGAS]

ANYONE PAYS CLOSE ATTENTION TO THE FILINGS OF THIS FAILED BIOTECH.

Will understand why investors are down 71%.

And will continue to lose 90% of all prospective new drugs fail to reach approval.

[linkvest]

Unity Biotechnology posts biggest intraday gain after Q3 earnings
Nov. 10, 2021

With the biggest ever intraday gain, Unity Biotechnology (UBX +30.0%) is trading near a two-month high after the company reported its Q3 2021 financials and provided business updates.

The highlights of the earnings release include upcoming milestones from biotech’s clinical studies on UBX1325 for patients with wet age-related macular degeneration (AMD).
In H1 2022, Unity (NASDAQ:UBX) expects to begin a Phase 2 proof of concept study for UBX1325 in AMD. The 12-week safety and efficacy data are expected in H2 2022.
Meanwhile, 12-week data from a Phase 2a proof of concept study for UBX1325 in diabetic macular edema (DME) are expected in H1 2022.
With $88.5M cash, cash equivalents, and marketable securities in hand, Unity (UBX) says its liquidity level is enough to fund operations through Q3 2022.

On Tuesday, the company released 24-week data from its Phase 1 single ascending dose (SAD) safety study for UBX1325 in DME.
The benefit from the treatment measured through best-corrected visual acuity (BCVA) reached a mean gain of 9.5 ETDRS letters for the higher doses with the effect lasting 24 weeks post-therapy, according to the results.
Now Read: Unity Biotechnology EPS beats by $0.09

[linkvest]

QUARTERLY IS OUT... 10Q:

https://ih.advfn.com/stock-market/NASDAQ/unity-biotechnology-UBX/stock-news/86516775/quarterly-report-10-q

[linkvest]

Tiny 1 to 3 share Bid whacks in an effort to scare folks LOL... this is the new bottom IMO.